global health 結果共36筆

Taiwan’s gymnastics team coach, Lin Yu-hsin, expressed confidence in the medal prospects of Tang Chia-hung and Olympic silver medalist Lee Chih-kai for the upcoming Paris Summer Olympics. The Taiwanese gymnasts recently visited the Accor Arena, the recognized gymnastics venue, and Lin confirmed that the warm-up venue adheres to global standards. Although no Taiwanese athlete has secured qualification yet, Lin believes that Lee’s performance in pommel horse, Tang’s performance in horizontal bar, and Lin Kuan-yi’s performance in rings could earn them a place in the Olympics and potentially podium finishes. The Accor Arena has hosted various sports events since 1984 and underwent recent renovations. Taiwan plans to send six participants, including Lee Chih-kai, Hsiao Yu-jan, Tang Chia-hung, Hung Yuan-hsi, Lin Kuan-yi, and Tseng Wei-sheng. Lin emphasized the importance of sending strong individual contestants focused on health to secure points. Lee Chih-kai and Tang Chia-hung, both recognized for their skilled performances and reputation, are expected to easily qualify due to their prime age.

Taiwan’s National Health Insurance (NHI) has achieved a satisfaction rate of 91.2% in 2023, according to the Ministry of Health and Welfare (MOHW). This is the first time the satisfaction rate has not decreased despite an increase in insurance costs. Previous reductions in satisfaction were observed in 2002 and 2006 due to premium increases, and in 2013 following the implementation of the second-generation NHI. The highest-rated aspects of the NHI were accessibility to medical treatment and the quality of medical care, with increased insurance costs ranking third. The satisfaction rate reached its peak during times of pandemic, likely due to the introduction of home-based medical care services and improved medical accessibility. Since 2021, the satisfaction rate has consistently remained above 90% and even reached a new all-time high during the pandemic. Taiwan has been ranked number one in the global healthcare index published by NUMBEO for the past five years. The NHI budget has also seen significant growth, increasing by over 48% from NT$590.5 billion in 2015 to NT$875.5 billion in 2024. The survey involved 3,257 participants aged 18 in Taiwan, and while public satisfaction with the NHI is high, physicians generally express lower levels of satisfaction.

Chinese children are increasingly experiencing antibiotic resistance when treating Mycoplasma pneumoniae, which poses a global health and economic concern. By 2050, drug-resistant diseases could result in healthcare costs of NT＄31 trillion and economic losses of up to NT＄106 trillion, according to the World Bank. The overuse of antibiotics has led to the rise of superbugs, diminishing the effectiveness of these medicines and compromising treatment outcomes. Azithromycin, a commonly used antibiotic in China for Mycoplasma pneumoniae, now faces an alarming resistance rate of nearly 80% to Macrolides. The World Health Organization (WHO) warns of the dangers of antibiotic overuse and refers to the situation as a ＂silent pandemic.＂ WHO Director-General Tedros Adhanom Ghebreyesus expresses concern that antibiotic resistance could bring us back to an era where minor infections are untreatable.

The Taiwanese government plans to allocate at least NT＄20 billion next year to raise the salaries of healthcare workers in response to recent protests by medical professionals. Premier Chen Chien-jen advocates for increased respect, appreciation, and compensation for frontline staff, stating that a health insurance system should not be built on the ＂sweat and tears＂ of healthcare professionals. Discussions are underway with President Tsai Ing-wen, National Health Insurance Administration Director-General Shih Chung-liang, and Health Minister Hsueh Jui-yuan on methods to enhance salaries through health insurance and public budget funds. The financial assistance will be directed at healthcare personnel excluding doctors, with specific details of the plan still under discussion. The Ministry of Health and Welfare has highlighted the global shortage of healthcare workers as a significant concern, and with COVID-19 still a threat, the government aims to increase healthcare investment and address the welfare of those on the medical frontline.

Professor May Oo Lwin from Nanyang Technological University spoke at the CTeC Asia event, warning against the dangerous rise in COVID-19 misinformation. Stressing the crucial role of media as a trustworthy information source, she called for public vigilance and cross-sector collaboration to counter disinformation.

Learn about the increasing cases of summer depression globally, exacerbated by extreme heat. Physicians emphasize prevention and self-care.

Taiwan’s highly praised healthcare system is facing financial challenges due to inflation and an aging population. The increase in medical expenses and the rising global budget of the National Health Insurance (NHI) has led experts to fear a potential rise in the premium rate next year. 

Following the U.S. Senate Intelligence Committee hearing on March 8, former U.S. National Security Council (NSC) official Jamie Metzl sat down with TVBS commentator Wenchi Yu to talk about the possible origins of the COVID-19 pandemic, and how understanding its origins could determine global health and safety in the future.

Giant, a global leader in the bicycle industry, announced on Dec. 9 that its revenue for the first 11 months of 2022 reached a total of NT$ 86.4 billion, seeing an annual increase of nearly 15%, a record high. However, the media reported that Giant recently sent letters to third-party manufacturers, mentioning that the bicycle industry is facing difficulties. 

全球疫苗分配不均的問題，已然成為國際間討論的重點，在各界輿論壓力下，歐盟、美國、加拿大等超量購買疫苗的地區，皆表示願意對外提供國內囤積的疫苗，協助全球加速疫苗接種。根據美國杜克大學全球衛生創新中心（Duke Global Health Innovation Center）數據指出，全球疫苗覆蓋率占比最高的前10名國家，皆為國際上屬於高收入的經濟體，其國內已購買的疫苗總量，估計可供每位居民皆種至少3次。

隨著台灣本土疫情加劇，疫苗成為各界熱烈討論的話題。目前在全球最熱門的疫苗廠牌分別為，輝瑞、阿斯特捷利康（AZ）、莫德納、嬌生四大龍頭。根據美國杜克大學全球衛生創新中心（Duke Global Health Innovation Center）統計至5月底數據顯示，國際間「高收入、中高收入、中低收入、低收入經濟體和COVID-19疫苗全球取得機制（COVAX）」，彼此購得的各廠牌疫苗數量可見，高收入經濟體多購買輝瑞及莫德納疫苗，部分地區也購買自家藥廠研發疫苗，但是並非所有疫苗都已獲得採購國的批准。